Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Stratification analysis of APOA1 -75 G/A polymorphisms in renal cancer cases

From: Apolipoprotein A1 -75 G/A and +83 C/T polymorphisms and renal cancer risk

  Cases GG GA AA
n (%) OR (95 %CI) P n (%) OR (95 %CI) P n (%) OR (95 %CI) P
Grade 216 108 (50.0) 1 (Reference)   66 (30.6) 1 (Reference)   42 (19.4) 1 (Reference)  
 1 55 28 (50.9) 1.02 (0.61,1.70) 0.95 15 (27.3) 0.89 (0.47,1.68) 0.73 12 (21.8) 1.12 (0.55,2.27) 0.75
 2 129 64 (49.6) 0.99 (0.68,1.45) 0.97 42 (32.6) 1.07 (0.68,1.66) 0.78 23 (17.8) 0.92 (0.53,1.59) 0.76
 3 + 4 32 16 (50.0) 1.00 (0.53,1.90) 1.00 9 (28.1) 0.92 (0.42,2.03) 0.84 7 (21.9) 1.13 (0.47,2.72) 0.79
Tumor classification 216 108 (50.0) 1 (Reference)   66 (30.6) 1 (Reference)   42 (19.4) 1 (Reference)  
 T1 103 55 (53.4) 1.07 (0.72,1.59) 0.75 29 (28.2) 0.92 (0.56,1.51) 0.75 19 (18.4) 0.95 (0.53,1.71) 0.86
 T2 49 22 (44.9) 0.90 (0.52,1.56) 0.70 16 (32.7) 1.07 (0.57,2.00) 0.84 11 (22.4) 1.16 (0.56,2.40) 0.70
 T3 57 28 (49.1) 0.98 (0.59,1.63) 0.95 19 (33.3) 1.09 (0.61,1.96) 0.77 10 (17.6) 0.90 (0.43,1.91) 0.79
 T4 7 3 (42.8) 0.86 (0.22,3.38) 0.83 2 (28.6) 0.94 (0.19,4.61) 0.93 2 (28.6) 1.47 (0.29,7.32) 0.64
Lymph node invasion status 216 108 (50.0) 1 (Reference)   66 (30.6) 1 (Reference)   42 (19.4) 1 (Reference)  
 Negative 199 99 (49.7) 0.99 (0.71,1.39) 0.98 61 (30.7) 1.00 (0.67,1.49) 0.99 39 (19.6) 1.01 (0.63,1.62) 0.97
 Positive 17 9 (52.9) 1.06 (0.46,2.45) 0.89 5 (29.4) 0.96 (0.34,2.71) 0.94 3 (17.7) 0.91 (0.26,3.24) 0.88
Distant metastasis status 216 108 (50.0) 1 (Reference)   66 (30.6) 1 (Reference)   42 (19.4) 1 (Reference)  
 Negative 188 99 (52.7) 1.05 (0.75,1.47) 0.76 59 (31.4) 1.03 (0.69,1.54) 0.90 30 (15.9) 0.82 (0.49,1.36) 0.45
 Positive 28 9 (32.1) 0.64 (0.29,1.41) 0.27 7 (25.0) 0.82 (0.34,1.96) 0.65 12 (42.9) 2.20 (1.04,4.68) 0.04
Pathology 216 108 (50.0) 1 (Reference)   66 (30.6) 1 (Reference)   42 (19.4) 1 (Reference)  
 Clear cell carcinoma 197 99 (50.2) 1.01 (0.72,1.40) 0.98 60 (30.5) 1.00 (0.67,1.49) 0.99 38 (19.3) 0.99 (0.61,1.60) 0.97
 Granular cell carcinoma 15 7 (46.7) 0.93 (0.37,2.36) 0.88 5 (33.3) 1.09 (0.38,3.11) 0.87 3 (20.0) 1.03 (0.29,3.71) 0.97
 Chromophobe cell carcinoma 4 2 (50.0) 1.00 (0.18,5.55) 1.00 1 (25.0) 0.82 (0.09,7.45) 0.86 1 (25.0) 1.29 (0.14,11.79) 0.82